RxDoctor Payments Data

Kaoru Pridgen, MD

Family Medicine · Columbia, SCNPI 1790755353

Payments from drug & device makers

$5,826in general payments, 2019–2025

Across 363 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$780
  • Novo Nordisk$454
  • AstraZeneca$332
  • Lilly USA, LLC$294
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$283
  • Pfizer$265
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$5,71198%
  • Other$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,826 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$156,884
Medicare patients
277
Services billed
3,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$47,756
OzempicSemaglutide29$32,208
UbrelvyUbrogepant13$26,834
EliquisApixaban33$25,443
JardianceEmpagliflozin13$22,455
MyrbetriqMirabegron16$18,789
TrulicityDulaglutide11$10,820
LinzessLinaclotide12$10,044
Mirabegron ErMirabegron13$8,024
JanumetSitagliptin Phos/Metformin Hcl12$6,564
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$5,919
SymproicNaldemedine Tosylate11$5,709
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$3,807
Levothyroxine Sodium193$3,007
Esomeprazole Magnesium38$2,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$294$58,57647 claims
AbbVieUbrelvy, Linzess, Synthroid$780$38,25642 claims
Novo NordiskOzempic$454$32,20829 claims
PfizerEliquis$265$25,44333 claims
Boehringer IngelheimJardiance$66$22,45513 claims
Astellas Pharma US IncMyrbetriq$47$18,78916 claims
MerckJanumet$54$6,56412 claims
GSKShingrix$93$2,46111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →